Hui Shao,
Assistant Professor
Department:
Pharmaceutical Outcomes & Policy
Business Phone:
(352) 294-8323
Business Email:
hui.shao@ufl.edu
Teaching Profile
Courses Taught
2020-2023
PHA5267 Prin Pharm-Economics
2021-2023
PHA6940 Supervised Teaching
2021-2022
PHA6971 Research for Master’s Thesis
2020-2022
PHA6935 Selected Topics in Pharmacy
2020-2023
PHA6910 Supervised Research
2021-2022
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy
2020-2023
PHA7979 Advanced Research
2021-2023
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2021-2023
PHA6936 Advanced Topics in Pharmaceutical Sciences
2021-2023
PHA6937 Topics in Pharmaceutical Administration
2020-2021
PHA7980 Research for Doctoral Dissertation
2019
PHA5878C Pt Care 3: Cv and Pulm
2023
PHA6946 Practicum in the Pharmaceutical Sciences
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-4088-546X
Publications
2023
A prediction model on incident chronic kidney disease among individuals with type 2 diabetes in the United States
Diabetes, Obesity and Metabolism.
25(10):2862-2868
[DOI] 10.1111/dom.15177.
2023
Changes in racial and ethnic disparities in glucose‐lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005‐2018
Diabetes, Obesity and Metabolism.
25(2):516-525
[DOI] 10.1111/dom.14894.
[PMID] 36251173.
2023
Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
Journal of managed care & specialty pharmacy.
29(8):884-895
[DOI] 10.18553/jmcp.2023.29.8.884.
[PMID] 37523313.
2023
Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.
Journal of the American Geriatrics Society.
71(7):2096-2106
[DOI] 10.1111/jgs.18306.
[PMID] 36821780.
2023
Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample
Annals of Internal Medicine.
176(4):582-583
[DOI] 10.7326/m22-3051.
2022
A machine learning approach identifies modulators of heart failure hospitalization prevention among patients with type 2 diabetes: A revisit to the ACCORD trial.
Journal of diabetes and its complications.
36(9)
[DOI] 10.1016/j.jdiacomp.2022.108287.
[PMID] 36007486.
2022
A National Catalog of Mapped Short-Form Six-Dimension Utility Scores for Chronic Conditions in the United States From 2010 to 2015.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
25(8):1328-1335
[DOI] 10.1016/j.jval.2022.02.011.
[PMID] 35367137.
2022
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.
Diabetes therapy : research, treatment and education of diabetes and related disorders.
13(9):1659-1670
[DOI] 10.1007/s13300-022-01300-5.
[PMID] 35930188.
2022
Economic Evaluation of the $35 Insulin Copay Cap Policy in Medicare and Its Implication for Future Interventions
Diabetes Care.
45(11):e161-e162
[DOI] 10.2337/dc22-1230.
[PMID] 36099174.
2022
Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.
Journal of diabetes and its complications.
36(3)
[DOI] 10.1016/j.jdiacomp.2022.108132.
[PMID] 35101326.
2022
Growing global burden of type 1 diabetes needs multitiered precision public health interventions.
The lancet. Diabetes & endocrinology.
10(10):688-689
[DOI] 10.1016/S2213-8587(22)00257-1.
[PMID] 36113506.
2022
Lowering hemoglobin A1c level to less than 6.0% in people with type 2 diabetes may reduce major adverse cardiovascular events: a Bayesian’s narrative.
Current medical research and opinion.
38(11):1883-1884
[DOI] 10.1080/03007995.2022.2129234.
[PMID] 36164760.
2022
Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials.
Journal of the American Geriatrics Society.
70(9):2719-2722
[DOI] 10.1111/jgs.17895.
[PMID] 35612586.
2022
Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes.
JAMA network open.
5(4)
[DOI] 10.1001/jamanetworkopen.2022.7705.
[PMID] 35435970.
2022
Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM‐CURE risk score
Diabetes, Obesity and Metabolism.
24(11):2203-2211
[DOI] 10.1111/dom.14806.
[PMID] 35801340.
2022
Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare
Diabetes Care.
45(8):1814-1821
[DOI] 10.2337/dc21-2601.
[PMID] 35700384.
2022
Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes
Diabetes Care.
45(2):e32-e33
[DOI] 10.2337/dc21-1800.
2022
Syndromic Surveillance Systems for Mass Gatherings: A Scoping Review.
International journal of environmental research and public health.
19(8)
[DOI] 10.3390/ijerph19084673.
[PMID] 35457541.
2022
Using modern risk engines and machine learning/artificial intelligence to predict diabetes complications: A focus on the BRAVO model.
Journal of diabetes and its complications.
36(11)
[DOI] 10.1016/j.jdiacomp.2022.108316.
[PMID] 36201893.
2021
A varied approach to left ventricular assist device follow-up improves cost-effectiveness.
Current medical research and opinion.
37(9):1501-1505
[DOI] 10.1080/03007995.2021.1948395.
[PMID] 34181489.
2021
Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
Journal of diabetes and its complications.
35(9)
[DOI] 10.1016/j.jdiacomp.2021.107972.
[PMID] 34247911.
2021
Comparing the downstream costs and healthcare utilization associated with the use of low-dose computed tomography (LDCT) in lung cancer screening in patients with and without alzheimer’s disease and related dementias (ADRD).
Current medical research and opinion.
37(10):1731-1737
[DOI] 10.1080/03007995.2021.1953972.
[PMID] 34252317.
2021
Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
24(2):227-235
[DOI] 10.1016/j.jval.2020.09.010.
[PMID] 33518029.
2021
The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018.
Current medical research and opinion.
37(11):1875-1880
[DOI] 10.1080/03007995.2021.1971181.
[PMID] 34429001.
2021
Trends in Total and Out-of-pocket Payments for Insulin Among Privately Insured U.S. Adults With Diabetes From 2005 to 2018
Diabetes Care.
44(10):e180-e182
[DOI] 10.2337/dc20-2529.
2021
Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018
Diabetes Care.
44(4):925-934
[DOI] 10.2337/dc20-2871.
2020
Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306
Diabetes Care.
43(2):e25-e25
[DOI] 10.2337/dc19-1891.
[PMID] 31959647.
2020
Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005–2007 and 2015–2017
Diabetes Care.
43(10):2396-2402
[DOI] 10.2337/dc19-2273.
[PMID] 32737138.
2020
Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study
Diabetes Care.
43(11):2847-2852
[DOI] 10.2337/dc20-0465.
[PMID] 32887705.
2020
Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults.
Journal of the American Heart Association.
9(24)
[DOI] 10.1161/JAHA.120.018233.
[PMID] 33317368.
2020
Trajectories of Short Physical Performance Battery Are Strongly Associated with Future Major Mobility Disability: Results from the LIFE Study.
Journal of clinical medicine.
9(8)
[DOI] 10.3390/jcm9082332.
[PMID] 32707877.
2020
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors
Diabetes Care.
43(7):1530-1536
[DOI] 10.2337/dc20-0227.
[PMID] 32345650.
2019
Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
22(12):1402-1409
[DOI] 10.1016/j.jval.2019.08.007.
[PMID] 31806197.
2019
Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis
Diabetes Care.
42(11):2136-2142
[DOI] 10.2337/dc19-0381.
Grants
Sep 2022
– Dec 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV
via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022
– Dec 2022
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention and Its Real-world Effectiveness and Cost-effectiveness among US Veterans
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020
ACTIVE
Using Real-world Data to Assess the Burden of Diabetes in Children and Adolescents in Florida
Role: Project Manager
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020
– Sep 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV
via CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2020
– Jul 2021
Simulating Long-Term Outcomes for iGlarlixi using BRAVO Diabetes Model
Role: Principal Investigator
Funding: TULANE UNIV
via SANOFI
Jun 2020
– Jun 2022
CDC IPA – Assignment Agreement 20IPA2008335DPG
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Contact Details
Phones:
- Business:
- (352) 294-8323
Emails:
- Business:
- hui.shao@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100496
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100496
GAINESVILLE FL 32610
Recent news
Dr. Hui Shao elected Director of Academics for the China Health Policy and Management Society
As Director of Academics, Shao will organize CHPAMS’ annual conference and develop two webinar series focused on introducing advanced methods in health economics and health services research and issues-driven research…
Dr. Hui Shao earns Early Career Award from CDC
The Centers for Disease Control and Prevention, or CDC, Health Economics Research Group bestowed Hui Shao, M.D., Ph.D., an assistant professor of pharmaceutical outcomes and policy, with the Kaafee Billah…